[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukemia-both-all-and-aml\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukemia-both-all-and-aml":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100627610","symptom-cluster-heterogeneity-and-gut-microbiota-mechanisms-in-childhood-cancer-survivors-100627610",false,"NCT07450872","Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors","A Multicenter Study on the Heterogeneity of Symptom Clusters and the Underlying Mechanisms of Gut Microbiota and Metabolites Among Childhood Cancer Survivors","SC-Het-GM-CCS","Inclusion Criteria for Children:\n\n* Aged 8-18 years;\n* Clinically and pathologically confirmed diagnosis of cancer (including leukemia, lymphoma, central nervous system tumors, or other common solid tumors);\n* Currently in the rehabilitation\u002Fmaintenance phase or completed treatment ≥6 months prior to enrollment;\n* No cognitive impairment; able to understand, communicate, and complete questionnaires independently;\n* Written informed consent\u002Fassent obtained from participants and their legal guardians.\n\nExclusion Criteria for Children:\n\n* Presence of severe treatment-related sequelae (e.g., significant organ dysfunction or neurological impairment) that may interfere with symptom assessment;\n* Poor compliance or inability to independently complete interviews\u002Fquestionnaires;\n* Concurrent participation in other interventional clinical trials that may influence study outcomes;\n* Planned major surgery or initiation of new chemotherapy\u002Fradiotherapy during the study period.\n\nInclusion Criteria for Caregivers:\n\n* Primary caregiver of an eligible CCS participant;\n* Aged ≥20 years;\n* Able to understand study content and complete questionnaires, with adequate literacy and communication ability;\n* Written informed consent provided prior to participation.\n\nExclusion Criteria for Caregivers:\n\n* Experience of major adverse life events within the past 6 months (e.g., bereavement, divorce) that may affect psychological assessment\n* Presence of severe cognitive impairment;\n* Presence of severe aphasia, psychiatric disorders, or other conditions preventing independent completion of assessments.","ALL","8 Years","18 Years",{"count":21,"type":22},600,"ESTIMATED","6 Months","OBSERVATIONAL","Advances in medical care have significantly improved survival among children with cancer. In China, the 5-year survival rate has reached 71.9%. Despite these improvements, many survivors continue to experience multiple co-occurring symptoms, such as fatigue, pain, sleep disturbance, and depression, which may adversely affect their quality of life.\n\nThese symptoms often occur together as symptom clusters and may reflect shared underlying biological mechanisms. This study aims to characterize symptom clusters among childhood cancer survivors and to explore their potential biological basis.\n\nParticipants will complete questionnaire assessments at multiple time points to evaluate symptom patterns and changes over time. In addition, stool samples will be collected to analyze gut microbiota composition and metabolite profiles. The study will examine the associations between symptom clusters and gut microbiota-metabolite features.\n\nFindings from this study are expected to improve understanding of symptom burden in childhood cancer survivors and to provide evidence for the development of targeted symptom management strategies.",[27,28,29],"Cancer","Glioma","Leukemia (Both ALL and AML)",[31,32,33],"symptom cluster","childhood cancer survivors","gut microbiat","RECRUITING","2026-06-03",{"date":37,"type":38},"2026-06-05","ACTUAL",{"date":40,"type":38},"2026-01-01",{"date":42,"type":22},"2028-12-31",{"name":44,"class":45},"The Children's Hospital of Zhejiang University School of Medicine","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":73,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":5},"100632820","phase-1-phase-i-clinical-trial-of-thinkk-adoptive-immunotherapy-after-allogeneic-hematopoietic-transplantation-in-children-with-leukemia-or-neuroblastoma-100632820","NCT07518654","Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma","Phase I Clinical Trial of Therapeutic Inducers of Natural Killer Killing (ThINKK) Adoptive Immunotherapy: Feasibility, Safety and Pharmacodynamics in Children Undergoing Allogenic Hematopoietic Transplantation for Leukemia or Neuroblastoma","ThINKK-01","Inclusion Criteria:\n\n1. Between 2 and less than 13 years old at time of informed consent form signature.\n2. Diagnosis of acute leukemia or neuroblastoma.\n3. Allogenic hematopoietic stem cell transplantation 30 to 90 days prior to eligibility confirmation.\n4. Blood NK cell counts ≥ 100 x 10E+6 cells\u002FL at least once before eligibility confirmation.\n5. Life expectancy of ≥ 3 months per investigator's judgment at time of eligibility confirmation.\n6. Patient or legally acceptable representative has provided informed consent based on local regulations and\u002For guidelines prior to any study-specific activities\u002Fprocedures being initiated.\n\nExclusion Criteria:\n\n1. Current grade 3 or 4 acute GvHD (per MAGIC criteria).\n2. Relapse of primary malignancy, or any other active malignancy.\n\n   1. For leukemia, defined as either morphological relapse or Minimal Residual Disease (MRD) ≥0.01% as measured by flow cytometry. MRD detected by polymerase chain reaction (PCR) does not constitute an exclusion criterion.\n   2. For neuroblastoma, defined as a progressive disease.\n3. Ongoing therapy with systemic corticosteroids (equivalent to a prednisone dose \\>0.5 mg\u002Fkg\u002Fday). Patients actively undergoing corticosteroid tapering during Screening may be enrolled once they have reached a prednisone-equivalent dose ≤ 0.5 mg\u002Fkg\u002Fday with Sponsor-Investigator approval, with the expectation that the taper will continue.\n4. Ongoing systemic therapy with cyclosporine.\n5. Administration or planned administration of any prohibited treatment listed in ad hoc section.\n6. Aspartate aminotransferase and alanine aminotransferase serum levels ≥5 times the upper limit of normal.\n7. Direct bilirubin serum levels ≥3 times the ULN (unless due to Gilbert syndrome).\n8. Baseline estimated glomerular filtration rate \\\u003C 50 mL\u002Fmin\u002F1.73 m2, as determined using the Bedside Schwartz equation for \\\u003C 18 years of age.\n9. Grade 4 diarrhea (ie, life-threatening consequences with urgent intervention indicated).\n10. O2 Sat saturation \\\u003C90% on room air by pulse oximetry.\n11. Uncontrolled life-threatening symptomatic infection(s).\n12. Blood pressure below the 5th percentile for age, sex, and height last 24 hours.\n13. Ongoing therapy with intravenous vasopressor agent.\n14. Any condition that, in the opinion of the Investigator, would compromise the safety of the patient, would prevent full participation in this study, or would interfere with the evaluation of any study endpoints.\n15. Pregnancy or breastfeeding or absence of highly effective methods of contraception for males and females of childbearing potential who engage in heterosexual intercourse","2 Years","12 Years",{"count":58,"type":22},12,"INTERVENTIONAL",[61],"PHASE1","A first-in-class adoptive immunotherapy we called ThINKK, for Therapeutic Inducers of Natural Killer (NK) cell Killing, have been designed for use after hematopoietic stem cell transplantation (HSCT), where the proper stimulation of graft-derived NK cells has been shown to prevent relapse.\n\nThINKK immunotherapy builds on our earlier research on NK cells and plasmacytoid dendritic cells (PDC) in cord blood and after HSCT. PDC are the sentinels of the immune system. Upon viral nucleic acids detection, PDC secrete a vast array of chemokines and cytokines that stimulate NK cells. PDC stimulation enhances NK cells killing of infected cells that express stress-induced molecules. Cancer cells also express stress-related molecules at their surface. However, NK cells do not receive PDC stimulation when fighting cancer. ThINKK therapy is designed to provide this necessary stimulation.",[64,65,66,67,68,69,29,70,71,72],"Leukaemia (Acute Lymphoblastic)","Leukaemia (Acute Myeloid)","Neuroblastoma","Neuroblastoma, Metastatic","Leukaemia, Lymphoblastic, Acute","Leukemia Acute Myeloid","Leukemia Acute Myeloid - AML","Hematopoetic Stem Cell Transplantation","Hematopoetic Stem Cell Transplant",[74,75,76,77],"Thinkk","NK cells","pdc","immunotherapy","NOT_YET_RECRUITING","2026-04-02",{"date":81,"type":38},"2026-04-08",{"date":83,"type":22},"2026-05-01",{"date":85,"type":22},"2029-05-01",{"name":87,"class":45},"Michel Duval"]